Plasminogen activator, specifically human tissue-type plasminogen activator (tPA), is a serine protease that plays a crucial role in the fibrinolytic system, which is responsible for the breakdown of blood clots. The substance is synthesized primarily in endothelial cells and is involved in converting plasminogen into plasmin, the enzyme that dissolves fibrin clots. The sequence mentioned, including specific amino acids such as L-asparagine and L-glutamine, indicates its precise structure, which is essential for its biological activity. tPA is characterized by its ability to bind to fibrin, enhancing its catalytic efficiency in clot lysis. It is also notable for its therapeutic applications, particularly in the treatment of acute ischemic stroke and myocardial infarction, where rapid clot dissolution is critical. The CAS number 191588-94-0 uniquely identifies this specific form of tPA, facilitating its recognition in scientific literature and regulatory contexts. Overall, tPA is a vital component in both physiological processes and clinical interventions related to thrombolysis.

Plasminogen activator, (human tissue-type), 103-L-asparagine-117-L-glutamine-296-L-alanine-297-L-alanine-298-L-alanine-299-L-alanine-

191588-94-0: Plasminogen activator, specifically human tissue-type plasminogen activator (tPA), is a serine protease that plays a crucial role in the fibrinolytic system, which is responsible for the breakdown of blood clots. The substance is synthesized primarily in endothelial cells and is involved in converting plasminogen into plasmin, the enzyme that dissolves fibrin clots. The sequence mentioned, including specific amino acids such as L-asparagine and L-glutamine, indicates its precise structure, which is essential for its biological activity. tPA is characterized by its ability to bind to fibrin, enhancing its catalytic efficiency in clot lysis. It is also notable for its therapeutic applications, particularly in the treatment of acute ischemic stroke and myocardial infarction, where rapid clot dissolution is critical. The CAS number 191588-94-0 uniquely identifies this specific form of tPA, facilitating its recognition in scientific literature and regulatory contexts. Overall, tPA is a vital component in both physiological processes and clinical interventions related to thrombolysis.

<p>Enecteplase is a 527 amino acid glycoprotein developed by introducing the following 3 modifications to the complementary DNA for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.  It binds to the fibrin component of the blood clot (thrombus) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus.</p>

CAS 191588-94-0

Plasminogen activator, (human tissue-type), 103-L-asparagine-117-L-glutamine-296-L-alanine-297-L-alanine-298-L-alanine-299-L-alanine-

Tenecteplase

Ref: 3D-FT168545